

HIV Glasgow 2024: Scientific Programme

Sunday 10 November

10:30–12:00	NEAT ID Studies and Updates <i>A workshop organised by the NEAT ID Foundation</i>
10:30–12:00	STEPS to curing HIV <i>A workshop by the European AIDS Treatment Group (EATG)</i>
12:00–12:30	Coffee, Posters and Exhibition
12:30–13:30	Industry Symposium
13:30–14:15	Lunch, Posters and Exhibition
14:15–15:15	Industry Symposium
15:15–15:30	Coffee
15:30–17:00	Industry Symposium
17:00–17:30	Coffee, Posters and Exhibition
17:30–17:50	Official Opening, Welcome from Glasgow City, and Outcomes, public health responses, lessons learned and current status of the Glasgow HIV outbreak (10 year overview)
17:30–17:40	Alexandra Calmy , <i>HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</i> Chloe Orkin , <i>Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i>
17:40–17:45	<i>Representative from Glasgow City Council, Glasgow, UK</i> and
17:45–17:50	Erica Peters , <i>Infectious Diseases Department, NHS Greater Glasgow and Clyde, Glasgow, UK</i>
17:50–19:00	Stigma in HIV, Past, Present and Future. Stereotyping Patients: Impact on HIV Treatment Co-chairs: Alexandra Calmy Chloe Orkin
17:50–17:55	Welcome and Introduction
17:55–18:10	Rigmor C Berg , <i>Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway</i>
18:10–18:25	Angelina Namiba , <i>4M Mentor Mothers Network, London, UK</i>
18:25–18:40	Teymur Noori , <i>HIV and Migrant Health, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden</i>
18:40–19:00	Panel Discussion and close
19:00–20:00	Welcome Reception

Monday 11 November

08:30–09:45 **Experience in the Implementation of Long-Acting Treatment
Session in collaboration with the International AIDS Society**

Co-chairs: **Cissy Kityo**, *Joint Clinical Research Centre, Kampala, Uganda*
Simon Collins, *HIV i-Base, United Kingdom*

08:30–08:35 **Welcome and Introduction**
Cissy Kityo

08:35–18:45 **Long-acting treatment for virally suppressed individuals**
Chloe Orkin, *Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK*

08:45–09:00 **Long-acting treatment for non-virally suppressed individuals on cabotegravir + rilpivirine: real world evidence**
Monica Gandhi, *Division of HIV, Infectious Diseases, and Global Medicine at University of California San Francisco / San Francisco General Hospital, San Francisco, CA, USA*

09:00–09:30 **Oral papers x 3**

09:30–09:45 **Panel discussion and close**
All

09:45–10:15 **Coffee, Posters and Exhibition**

10:15–11:15 **Managing Cardiometabolic Risk in HIV: The Role of Old and New Drugs**

Co-chairs: **Bernard Surial**, *Department of Infectious Diseases, University Hospital of Bern, Bern, Switzerland*
Andrew Carr, *Immunology and HIV Unit, St Vincent's Hospital; and University of New South Wales, Sydney, Australia*

10:15–10:20 **Welcome and Introduction**
Bernard Surial

10:20–10:33 **Managing cardiovascular disease risk in HIV**
Esteban Martinez, *Infectious Diseases Unit, Hospital Clínic de Barcelona, Barcelona, Spain*

10:33–10:46 **GLP-1 agonists to mitigate cardiometabolic risk (incl role in obesity, diabetes and primary CVD prevention)**

10:46–10:59 **Managing ART-associated weight gain in HIV**
Cristina Mussini, *Department of Infectious Diseases and Tropical Medicine, University Hospital, Modena, Italy*

10:59–11:15 **Panel discussion and close**
All, joined by **Nadine Jaschinski**, *The International Cohort Consortium of Infectious Disease (RESPOND)*, and **CHIP**, *Rigshospitalet, Copenhagen, Denmark*

11:15–12:30 **Elimination of HIV Vertical Transmission Across the World
In collaboration with the Euroguidelines in Central and Eastern Europe (ECEE) Network Group**

Co-chairs: **Linda-Gail Bekker**, *Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa*

Cristiana Oprea, *Department of Infectious Diseases, Epidemiology, Microbiology, Parasitology, Virology, Diabetes, Endocrinology, University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania*

- 11:15–11:20 **Welcome and Introduction**
Cristiana Oprea
- 11:20–11:35 **Triple elimination initiative of mother-to-child transmission of HIV, syphilis and hepatitis B**
- 11:35–11:47 **Human rights and elimination of HIV vertical transmission, including co-infection – insights from Eastern Europe and Central Asia**
Justyna Kowalska, *Department of Adult Infection Diseases, Medical University of Warsaw, Warsaw, Poland; and HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland*
- 11:47–11:59 **Sexual violence, HIV and pregnancy outcomes in South America**
Claudia Cortes, *Faculty of Medicine, University of Chile, Santiago, Chile*
- 11:59–12:11 **Early infant diagnosis and linkage to HIV care for children – are we there yet?**
Oxana Turcanu, *Perinatal Center, Clinical Municipal Hospital "Gheorghe Paladi", Chişinău, Moldova*
- 12:11–12:30 **Panel discussion and close**
All
- 12:30–13:45 **Lunch, Posters and Exhibition**
- 12:45–13:45 **Industry Symposium**
- 13:45–14:30 **Antiretroviral Treatment Strategies**
Co-chairs: **Magdalena Ankiersztejn-Bartczak**, *Foundation for Social Education, Warsaw, Poland*
Alexandra Calmy, *HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland*
- 13:45–13:50 **Welcome and introduction**
Alexandra Calmy
- 13:50–14:10 **New Treatments and Future Combinations**
Jose Arribas, *Infectious Diseases Unit, La Paz Hospital, Madrid, Spain; and School of Medicine, Autonoma University School of Medicine, Madrid, Spain*
- 14:10–14:20 **Oral paper**
- 14:20–14:30 **Panel discussion and close**
All
- 14:30–15:45 **Infection Prevention**
Chair: **Iskandar Azwa**, *University Malaya, Kuala Lumpur, Malaysia*
- 14:30–14:35 **Welcome and introduction**
Iskandar Azwa
- 14:35–14:45 **A provider's perspective of DoxyPEP**
Jade Ghosn, *Department of Infectious Diseases, Bichat University Hospital, Paris, France*

- 14:45–14:55 **A DoxyPEP perspective from the community**
Sophie Strachan, *The Sophia Forum, London, UK; and Chelsea and Westminster Hospital NHS Foundation Trust, London, UK*
- 14:55–15:05 **Oral paper**
- 15:05–15:20 **Mpox: WHO Update**
- 15:20–15:30 **Oral paper**
- 15:30–15:45 **Panel discussion and close**
All
- 15:45–17:00 **Supporting an Older Population of People Living With HIV, or at Risk of HIV**
In collaboration with the British HIV Association
- Co-chairs:** **Giovanni Guaraldi**, *Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy*
Nicoletta Policek, *UK Community Advisory Board (UK-CAB), UK*
- 15:45–15:50 **Welcome and Introduction**
Co-chair
- 15:50–16:00 **Global perspectives on HIV in older people**
Caroline Sabin, *Institute for Global Health, University College London (UCL), London, UK*
- 16:00–16:10 **Models of care for older people with HIV**
Tristan Barber, *Ian Charleson Day Centre, Royal Free Hospital, London, UK*
- 16:10–16:20 **Are we adequately supporting women ageing with HIV?**
Yvonne Gilleece, *Claude Nicol Centre (Sexual Health) and Lawson Unit (HIV), Brighton and Sussex University Hospitals NHS Trust, Brighton, UK*
- 16:20–16:30 **PrEP in older people at risk of HIV acquisition**
Juddy Otti-Olunga, *HIV Services, Africa Advocacy Foundation, and The Sophia Forum, London, UK*
- 16:30–16:40 **Adults with perinatally acquired HIV: emerging clinical outcomes and data gaps**
Merle Henderson, *Clinical Trials Centre, Imperial College Healthcare NHS Trust, London, UK*
- 16:40–17:00 **Panel discussion and close**
All
- 17:00–17:30 **Coffee, Posters and Exhibition**
- 17:30–19:00 **Industry Symposium**

Tuesday 12 November

- 08:30–09:30 **Industry Symposium**
- 09:30–09:45 **Coffee, Posters and Exhibition**

09:45–11:15	Integrase Strand Transfer Inhibitor (INSTI) Resistance
Co-chairs:	Anton Pozniak , <i>Chelsea and Westminster Hospital, London, UK</i> Marco Vitoria , <i>Department of HIV/AIDS, World Health Organization, Geneva, Switzerland</i>
09:45–09:50	Welcome and Introduction Anton Pozniak
09:50–10:05	INSTI resistance global data trends Daniel Kuritzkes , <i>Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA</i>
10:05–10:20	2nd generation INSTI resistance in randomized trials and cohorts Andrew Hill , <i>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK</i>
10:20–10:35	HIV drug resistance testing: new strategies and the promise of new technologies Gert Van Zyl , <i>Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</i>
10:35–10:55	Oral papers x 2
10:55–11:15	Panel discussion and close All, Led by Marco Vitoria , <i>Department of HIV/AIDS, World Health Organization, Geneva, Switzerland</i>
11:15–12:00	Keynote Lecture: Artificial Intelligence and Digital Technologies: Their Role in Future HIV Research, Treatment and Care
Chair:	Peter Hunt , <i>University of California, San Francisco, United States</i> Alastair C Van Heerden , <i>Center for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa; and SAMRC/Wits Developmental Pathways for Health Research Unit, University of the Witwatersrand, Johannesburg, South Africa</i>
12:00–13:00	HIV Cure: Lessons Learnt and Prospects for the Future
Co-chairs:	Peter Reiss , <i>Amsterdam UMC, University of Amsterdam in Amsterdam, The Netherlands</i> Alain Volny-Anne , <i>Paris, France</i>
12:00–12:05	Welcome and introduction to this year's Joep Lange and Jacqueline van Tongeren keynote lecture, dedicated to them in recognition of their commitment and passion to rid the world of HIV/AIDS Peter Reiss
12:05–12:30	Keynote – HIV cure: Lessons learnt and prospects for the future Linos Vandekerckhove , <i>Department of Internal Medicine and Pediatrics, HIV Cure Research Center, University Hospital Ghent, Ghent University, Ghent, Belgium</i>
12:30–12:45	Ethics in trials of HIV cure Karine Dube , <i>School of Medicine and Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA</i>
12:45–13:00	Panel discussion All joined by Sarah Fidler , <i>Imperial College NHS Trust, and Imperial College London, London, UK</i>

13:00–14:15	Lunch, Posters and Exhibition
13:15–14:15	Industry Symposium
14:15–15:30	Clinical Case Study Session <i>In collaboration with the Liverpool DDI team</i>
Facilitators:	Roy Gulick , <i>Department of Medicine, Weill Cornell Medicine, New York, NY, USA</i> Saye Khoo , <i>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK; and Royal Liverpool University Hospital, Liverpool, UK</i> Catia Marzolini , <i>Department of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; and Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; and School of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK</i>
Panellists:	Marta Boffito , <i>Clinical Research Facility / HIV Service, Chelsea and Westminster Hospital, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK</i> Lene Ryom , <i>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark</i> Claudia Cortes , <i>Faculty of Medicine, University of Chile, Santiago, Chile</i> Karine Lacombe , <i>Department of Infectious Diseases, Hospital Saint Antoine, Paris, France</i>
14:15–14:25	Celebrating 25 years of the work of the Liverpool DDI Team Saye Khoo
14:25–14:45	Case 1: Seroconversion on long-acting PrEP Jean-Michel Molina , <i>University of Paris, Paris, France; and Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, Paris, France</i>
14:45–15:05	Case 2: Low CV risk – statins case <i>Do you use them and what about DDIs?</i> Laura Waters , <i>Mortimer Market Centre, University College London Hospitals NHS Foundation Trust London, UK</i>
15:05–15:25	Case 3: TB with ART? Catherine Orrell , <i>Antiretroviral Treatment Division (ART), Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</i>
15:25–15:30	Close Saye Khoo
15:30–16:00	HIV in migrant populations <i>The Lancet HIV</i> <i>A ‘fireside chat’ between the session moderator and invited guests to learn more about The Lancet HIV’s upcoming paper series. The ‘chat’ will discuss how the concept came about, and explore the challenges faced along the way as the series progressed.</i>
Guests:	Claudia Cortes , <i>Faculty of Medicine, University of Chile, Santiago, Chile</i> Alena Kamenshchikova , <i>Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands</i>

16:00–17:00	Emerging Ethical and Participation Challenges in HIV Research and Development <i>in collaboration with the European AIDS Treatment Group (EATG)</i>
Co-chairs:	Aisuluu Bolotbaeva, EATG, Bishkek, Kyrgyzstan Mario Cascio, EATG, Palermo, Italy
16:00–16:05	Welcome and introduction Co-chair
16:05–16:15	The challenges of ATI in HIV cure research from the community perspective Gus Cairns, London, UK
16:15–16:25	Engagement with the community Grzegorz Jezierski, Warsaw, Poland
16:25–16:35	Bridging the gap: Ensuring gender equity in clinical trials for better health outcomes Oana Sandulescu, Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
16:35–16:45	Broadening horizons: Enhancing transgender inclusion and global diversity in clinical trials Amanita Calderon Cifuentes, Transgender Europe, Berlin, Germany
16:45–17:00	Discussion, Q&A and conclusions All
17:00–17:30	Coffee, Posters and Exhibition
17:30–19:00	Industry Symposium

Wednesday 13 November

08:30–09:45	Guidelines Session: 2024 Update and CV Risk Recommendations <i>in collaboration with the European AIDS Clinical Society (EACS)</i>
Co-chairs:	Jürgen Rockstroh, Department of Medicine I, University Hospital Bonn, Bonn, Germany; and German Centre for Infection Research (DZIF), Bonn, Germany Juan Ambrosioni, HIV/AIDS Unit and Infectious Disease Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain
08:30–08:35	Welcome and introduction, and the 2024 EACS guidelines: new format, new content and new terms of reference Juan Ambrosioni
08:35–08:45	Update on ART for treatment and prevention Laura Levi, Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, France
08:45–08:55	Update on co-infections, sexually transmitted infections and opportunistic infections Andrea Mastrangelo, Department of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland
08:55–09:05	Update on paediatric HIV management, vertical transmission and infant feeding Steven Welch, Department of Paediatrics, Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK

09:05–09:25	<p>Co-morbidities: update on cardiovascular and metabolic risk, including statins recommendations and other co-morbidities</p> <p>Jasmini Alagaratnam, <i>Department of Sexual Health & HIV, Chelsea & Westminster Hospital NHS Foundation Trust, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK</i></p>
09:25–09:45	<p>Panel discussion and closing remarks</p> <p>Esteban Martínez, <i>HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona, Barcelona, Spain; and University of Barcelona, Barcelona, Spain; and CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III, Madrid, Spain</i></p> <p>Catia Marzolini, <i>Department of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; and Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; and School of Molecular & Clinical Pharmacology, University of Liverpool, Liverpool, UK</i></p> <p>Luís Mendão, <i>GAT – Portuguese Activist Group on Treatments, Lisbon, Portugal</i></p> <p>Jean-Michel Molina, <i>University of Paris, Paris, France; and Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, Paris, France</i></p> <p>Cristiana Oprea, <i>Department of Infectious Diseases, Epidemiology, Microbiology, Parasitology, Virology, Diabetes, Endocrinology, University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania</i></p> <p>Steven Welch, <i>University Hospitals Birmingham NHS Foundation Trust, United Kingdom</i></p>
09:45–10:15	Coffee, Posters and Exhibition
10:15–11:45	<p>Co-morbidities and Co-infections</p> <p>Co-chairs: Karine Lacombe, <i>Department of Infectious Diseases, Hospital Saint Antoine, Paris, France</i> Milosz Parczewski, <i>Pomeranian Medical University, Szczecin, Poland</i></p>
10:15–11:45	Oral Papers x 6
11:45–12:50	<p>PrEP-ing for the Future</p> <p>Co-chairs: Alexandra Calmy, <i>HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</i> Chloe Orkin, <i>Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i></p>
11:45–12:05	<p>Keynote Lecture: PrEP Therapeutic Agents - What's on the Horizon and Access?</p> <p><i>Lock Lecture gifted by the Royal College of Physicians and Surgeons of Glasgow</i></p> <p>Linda-Gail Bekker, <i>Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</i></p>
12:05–12:35	Oral papers x 3
12:35–12:50	<p>Panel discussion and congress close</p> <p>All</p>
12:50–13:00	Congress close
13:00–13:45	Lunch, Posters and Departures